Evidence map›Paper›PMID 34535466›Full record

ArticleBMJ (Clinical research ed.)2021

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study.

Julia Hippisley-Cox, Carol Ac Coupland, Nisha Mehta, Ruth H Keogh, Karla Diaz-Ordaz, Kamlesh Khunti, Ronan A Lyons, Frank Kee, Aziz Sheikh, Shamim Rahman and 8 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in BMJ (Clinical research ed.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05852873 (PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway), which is not on this map. Cited by 202 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05852873 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

TypeinterventionalSponsorHaukeland University HospitalRan2023 to 2027Enrolled2,000ConditionsPost COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19ArmsNirmatrelvir/ritonavir, Placebo
3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Julia Hippisley-CoxNuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK julia.hippisley-cox@phc.ox.ac.uk.ORCID 0000-0002-2479-7283
Carol Ac CouplandNuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.
Nisha MehtaNHS-X, London, UK.
Ruth H KeoghDepartment of Medical Statistics and Centre for Statistical Methodology, London School of Hygiene and Tropical Medicine, London, UK.
Karla Diaz-OrdazDepartment of Medical Statistics and Centre for Statistical Methodology, London School of Hygiene and Tropical Medicine, London, UK.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester, UK.
Ronan A LyonsPopulation Data Science, Swansea University, Swansea, UK.
Frank KeeQueen's University, Belfast, UK.
Aziz SheikhUsher Institute, University of Edinburgh, Edinburgh, UK.
Shamim RahmanDepartment of Health and Social Care, England, UK.
Jonathan ValabhjiNIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Ewen M HarrisonUsher Institute, University of Edinburgh, Edinburgh, UK.
Peter SellenDepartment of Health and Social Care, England, UK.
Nazmus HaqDepartment of Health and Social Care, England, UK.
Malcolm G SempleNIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Peter W M JohnsonNHS England and Improvement, London, UK.
Andrew HaywardUCL Institute of Epidemiology and Health Care, London, UK.
Jonathan S Nguyen-Van-TamDivision of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.

Funding

Medical Research Council MC_PC_13043Medical Research Council MC_PC_19025Medical Research Council MR/K006525/1Medical Research Council MR/K023241/1Medical Research Council MR/S017968/1Medical Research Council MR/V028367/1
6 · The paper itself

Abstract

objectivesTo derive and validate risk prediction algorithms to estimate the risk of covid-19 related mortality and hospital admission in UK adults after one or two doses of covid-19 vaccination.

designProspective, population based cohort study using the QResearch database linked to data on covid-19 vaccination, SARS-CoV-2 results, hospital admissions, systemic anticancer treatment, radiotherapy, and the national death and cancer registries. SETTINGS: Adults aged 19-100 years with one or two doses of covid-19 vaccination between 8 December 2020 and 15 June 2021.

main outcome measuresPrimary outcome was covid-19 related death. Secondary outcome was covid-19 related hospital admission. Outcomes were assessed from 14 days after each vaccination dose. Models were fitted in the derivation cohort to derive risk equations using a range of predictor variables. Performance was evaluated in a separate validation cohort of general practices.

resultsOf 6 952 440 vaccinated patients in the derivation cohort, 5 150 310 (74.1%) had two vaccine doses. Of 2031 covid-19 deaths and 1929 covid-19 hospital admissions, 81 deaths (4.0%) and 71 admissions (3.7%) occurred 14 days or more after the second vaccine dose. The risk algorithms included age, sex, ethnic origin, deprivation, body mass index, a range of comorbidities, and SARS-CoV-2 infection rate. Incidence of covid-19 mortality increased with age and deprivation, male sex, and Indian and Pakistani ethnic origin. Cause specific hazard ratios were highest for patients with Down's syndrome (12.7-fold increase), kidney transplantation (8.1-fold), sickle cell disease (7.7-fold), care home residency (4.1-fold), chemotherapy (4.3-fold), HIV/AIDS (3.3-fold), liver cirrhosis (3.0-fold), neurological conditions (2.6-fold), recent bone marrow transplantation or a solid organ transplantation ever (2.5-fold), dementia (2.2-fold), and Parkinson's disease (2.2-fold). Other conditions with increased risk (ranging from 1.2-fold to 2.0-fold increases) included chronic kidney disease, blood cancer, epilepsy, chronic obstructive pulmonary disease, coronary heart disease, stroke, atrial fibrillation, heart failure, thromboembolism, peripheral vascular disease, and type 2 diabetes. A similar pattern of associations was seen for covid-19 related hospital admissions. No evidence indicated that associations differed after the second dose, although absolute risks were reduced. The risk algorithm explained 74.1% (95% confidence interval 71.1% to 77.0%) of the variation in time to covid-19 death in the validation cohort. Discrimination was high, with a D statistic of 3.46 (95% confidence interval 3.19 to 3.73) and C statistic of 92.5. Performance was similar after each vaccine dose. In the top 5% of patients with the highest predicted covid-19 mortality risk, sensitivity for identifying covid-19 deaths within 70 days was 78.7%.

conclusionThis population based risk algorithm performed well showing high levels of discrimination for identifying those patients at highest risk of covid-19 related death and hospital admission after vaccination.

Indexed as

AdultAgedAged, 80 and overBNT162 VaccineChAdOx1 nCoV-19ComorbidityCOVID-19COVID-19 VaccinesDatabases, FactualFemaleHospitalizationHumansMaleMiddle AgedProspective StudiesRisk AssessmentBNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccines

Identifiers

PMID34535466
PMCPMC8446717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.